"And we have one competitor, but between us and that one competitor, we have still only a very low level of patients receiving treatment in the US," Schultz said, according to a transcript of the call. "So we are quite convinced that this product can keep on growing for the foreseeable future." Teva is also expecting a readout for Austedo in Tourette's syndrome in early 2020, potentially opening the drug to another patient pool. Meanwhile, Schultz acknowledged that another recent launch, CGRP migraine med Ajovy, has had a less than stellar rollout so far.